New Zealand markets close in 5 hours 28 minutes
  • NZX 50

    12,671.05
    +34.50 (+0.27%)
     
  • NZD/USD

    0.7180
    +0.0006 (+0.08%)
     
  • ALL ORDS

    7,317.50
    +36.90 (+0.51%)
     
  • OIL

    63.37
    -0.09 (-0.14%)
     
  • GOLD

    1,764.60
    -2.20 (-0.12%)
     

Transparency Notification

Acacia Pharma Group plc
·3-min read

THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION.

PUBLICATION RELATING TO A TRANSPARENCY NOTIFICATION

(ARTICLE 14, 1ST PARAGRAPH, OF THE LAW OF 2 MAY 2007 ON THE DISCLOSURE OF MAJOR HOLDINGS)

Acacia Pharma Group plc

1. Summary of the notification

Cambridge, UK and Indianapolis, US – 26 February 2021, 08:00 CET: Acacia Pharma Group plc has received a transparency notification dated 23 February 2021 indicating that Cosmo Pharmaceuticals N.V now holds, by virtue of the issue of shares on 23 February 2021, 19.66% of the voting rights of the company. Cosmo has therefore crossed the threshold of 20%.

2. Content of notification
The notification dated 23 February 2021 contains the following information:

  • Reason of the notification – passive crossing of a threshold

  • Notification by – a parent undertaking or a controlling person

  • Persons subject to the notification requirement – Cosmo Pharmaceuticals N.V. Riverside 2, Sir John Rogerson’s Quay, Dublin 2, Ireland

  • Date on which the threshold is crossed – 23 February 2021

  • Threshold that is crossed – 20%

  • Denominator – 99,689,451

  • Notified details:

A) Voting rights

Previous notification

After the transaction

# of voting rights

# of voting rights

% of voting rights

Holders of voting rights

Linked to securities

Not linked to securities

Linked to securities

Not linked to securities

Cosmo Pharmaceuticals N.V.

0

0

0

0.00%

0.00%

Cosmo Technologies Ltd.

19,600,098

19,600,098

0

19.66%

0.00%

Subtotal

19,600,098

19,600,098

19.66%

TOTAL

19,600,098

0

19.66%

0.00%


B) Voting rights

After the transaction

Holders of equivalent financial instruments

Type of financial instrument

Expiration date

Exercise period or date

# of voting rights that may be acquired if the instrument is exercised

% of voting rights

Settlement

TOTAL

0

0.00%

TOTAL (A+B)

# of voting rights

% of voting rights

CALCULATE

19,600,098

19.66%

·Full chain of controlled undertakings through which the holding is effectively held: Cosmo Technologies Ltd is a 100% subsidiary of Cosmo Pharmaceuticals N.V.

  1. Miscellaneous

Contacts

Acacia Pharma Group plc
Mike Bolinder, CEO
Gary Gemignani, CFO
+44 1223 919760 / +1 317 505 1280
IR@acaciapharma.com

International Media
Mark Swallow, Frazer Hall, David Dible
Citigate Dewe Rogerson
+44 20 7638 9571
acaciapharma@citigatedewerogerson.com

US Investors
LifeSci Advisors
Irina Koffler
+1 917-734-7387
ikoffler@lifesciadvisors.com

Media in Belgium and the Netherlands
Chris Van Raemdonck
+32 499 58 55 31
chrisvanraemdonck@telenet.be

Acacia Pharma Group plc
The Officers’ Mess, Royston Road, Duxford, Cambridge, CB22 4QH, United Kingdom
Company number 9759376

About Acacia Pharma

Acacia Pharma is a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures, or cancer chemotherapy. The Company has identified important and commercially attractive unmet needs in these areas that its product portfolio aims to address.

Acacia Pharma's first product, BARHEMSYS® (amisulpride injection) is marketed in the US for the management of postoperative nausea & vomiting (PONV).

BYFAVO™ (remimazolam) for injection, a very rapid onset/offset IV benzodiazepine sedative is approved and launched in the US for use during invasive medical procedures in adults lasting 30 minutes or less, such as colonoscopy and bronchoscopy. BYFAVO is in-licensed from Paion UK Limited for the US market.

APD403 (intravenous and oral amisulpride), a selective dopamine antagonist for chemotherapy induced nausea & vomiting (CINV) has successfully completed one proof-of-concept and one Phase 2 dose-ranging study in patients receiving highly emetogenic chemotherapy.

Acacia Pharma has its US headquarters in Indianapolis, IN and its R&D operations are centered in Cambridge, UK. The Company is listed on the Euronext Brussels exchange under the ISIN code GB00BYWF9Y76 and ticker symbol ACPH.

www.acaciapharma.com

Attachment